BORTEZOMIB HYDRATE |
VELCADE |
LDP-341 |
BORTEZOMIB |
NSC-681239 |
PS-341 |
PS 341 |
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE |
VELCADE® |
PEPTIDE BORONATE |
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID |
drugbank:00188 |
rxcui:358258 |
chembl:CHEMBL325041 |
chemidplus:179324-69-7 |
pubchem.compound:387447 |
Year of Approval | 2003 |
Drug Class | antineoplastic agents |
FDA Approval | Multiple myeloma, Mantle cell lymphoma |
Drug Class | Small molecule inhibitor |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
Trial Name | Velcade |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
Trial Name | Velcade |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | Velcade |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
Trial Name | Velcade |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | Velcade |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | 26S proteosome inhibitor |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | 26S proteosome inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
Notes |
inhibitor (inhibitory) |
n/a |
BORTEZOMIB | Primary Drug Name |
Drug Class | antineoplastic agents |
Year of Approval | 2003 |
LDP341 | Development Name |
MLN341 | Development Name |
PS-341 | Development Name |
Drug Class | Small molecule inhibitor |
FDA Approval | Multiple myeloma, Mantle cell lymphoma |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
CHEMBL325041 | ChEMBL Drug ID |
C1851 | NCI drug code |
C1851 | NCI drug code |
D03AJX | TTD Drug ID |
BORTEZOMIB | Primary Drug Name |
BORTEZOMIB | Drug Generic Name |
VELCADE | Drug Trade Name |
D0SH3I | TTD Drug ID |